Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
July 31, 2014 2:17 PM EDTRoth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.
Ahead of the bell, Cytokinetics posted Q2 loss of $0.23 per share with revenue of $7.8 million, versus consensus estimates calling for a loss of $0.32 per share and revs of $7.0 million. Roth was looking for a loss of $0.38 per share and revenue of $4.0 million.
Roth analyst Joseph Pantginis... More
